Dr Reddy's launches anti-SRE drug in US

The drug is used for prevention of skeletal-related events in multiple types of advanced cancer involving the bone

Hyderabad-based pharmaceutical major Dr Reddy's Laboratories Limited launched its zoledronic acid injection in 4 mg/5 ml strength in the US market on March 4.

The launch follows US Food and Drug Administration's (USFDA) approval of its abbreviated new drug application for the drug.

A bio-equivalent generic version of Zometa (zoledronic acid), which is sold under the Reclast and Zometa brand names in the US, the drug is indicated for the prevention of skeletal-related events (SREs) in multiple types of advanced cancer involving the bone.

The zoledronic acid injection 4 mg/5 ml is available in a single-use vial of concentrate, Dr Reddy's said in a press release on Tuesday.

Dr Reddy's scrip is currently trading at Rs 1,782.90 on the BSE, up 1.06%, over the previous close of Rs 1,764.15 a share.